EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients

Micaela Ippoliti, Marzia Defina, Antonella Gozzini, Claudia Baratè, Lara Aprile, Alice Pietrini, Alessandro Gozzetti, Donatella Raspadori, Francesco Lauria, Monica Bocchia

Leukemia Research and Treatment · 2012

DOI: 10.1155/2012/150651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia Research and Treatment, 2012. Verfasst von Micaela Ippoliti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University of Siena, 53100 Siena, Italy. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ph+ acute lymphoblastic leukemia (Ph+ ALL) is a high-risk acute leukemia with poor prognosis, in which the specific t(9;22)(q34;q11) translocation results in a chimeric bcr-abl (e1a2 breakpoint) and in a 190 KD protein (p190) with constitutive tyrosine kinase activity. The advent of first- and second-generation tyrosine kinase inhibitors (TKIs) improved the short-term outcome of Ph+ ALL patients not eligible for allo-SCT; yet disease recurrence is almost inevitable. Peptides derived from p190-breakpoint area are leukemia-specific antigens that may mediate an antitumor response toward p190+ leukemia cells. We identified one peptide named p190-13 able to induce in vitro peptide-specific CD4+ T cell proliferation in Ph+ ALL patients in complete remission during TKIs. Thus this peptide appears a good candidate for developing an immune target vaccine strategy possibly synergizing with TKIs for remission maintenance.

Autor:innen und Institutionen

  • Department of Hematology, University of Siena, 53100 Siena, Italy.

Zitieren

APA

Ippoliti, M., Defina, M., Gozzini, A., Baratè, C., Aprile, L., Pietrini, A., Gozzetti, A., Raspadori, D., Lauria, F., & Bocchia, M. (2012). Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. Leukemia Research and Treatment. https://doi.org/10.1155/2012/150651

Vancouver

Ippoliti M, Defina M, Gozzini A, Baratè C, Aprile L, Pietrini A, et al. Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. Leukemia Research and Treatment. 2012. doi:10.1155/2012/150651

BibTeX
@article{Ippoliti2012,
  author = {Ippoliti, Micaela and Defina, Marzia and Gozzini, Antonella and Baratè, Claudia and Aprile, Lara and Pietrini, Alice and Gozzetti, Alessandro and Raspadori, Donatella and Lauria, Francesco and Bocchia, Monica},
  title = {Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients},
  journal = {Leukemia Research and Treatment},
  year = {2012},
  doi = {10.1155/2012/150651}
}
Kostenlos starten →